EPC 003
Alternative Names: EPC-003Latest Information Update: 07 May 2025
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glioblastoma
- No development reported Multiple myeloma
Most Recent Events
- 28 Apr 2025 Preclinical trials in Glioblastoma in USA (Parenteral) prior to April 2025
- 28 Apr 2025 Pharmacodynamics data from preclinical studies in Glioblastoma released by Elpis Biopharmaceuticals
- 28 Apr 2025 Elpis Biopharmaceuticals plans a proof of concept, investigator initiated trial for Glioblastoma (Second-line therapy or greater) (Parenteral),